<DOC>
	<DOC>NCT01565746</DOC>
	<brief_summary>This is an uncontrolled, open-label, non-randomized Phase I study to investigate safety, biodistribution, radiation dosimetry and pharmacokinetics of a single dose of BAY88-8223 in Japanese patients with castration-resistant prostate cancer and bone metastases.</brief_summary>
	<brief_title>Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Male â‰¥ 20 years of age Histologically or cytologically confirmed adenocarcinoma of the prostate Presents with at least 2 bone metastases, confirmed by scintigraphic imaging within the previous 4 weeks Patients who has failed initial hormonal therapy using either an orchiectomy or a Gonadotropin releasing hormone (GnRH) agonist in combination with an antiandrogen must first progress through antiandrogen withdrawal prior to being eligible. The minimum timeframe to document failure of antiandrogen withdrawal will be four weeks Progressive castration resistant metastatic disease Castrate level of testosterone (&lt;50 ng/dL), treatment to maintain castrate levels of testosterone must be continued Has received an investigational drug in the 4 weeks before or is scheduled to receiving one during or in the 8 weeks after study drug administration. Has received chemo, immuno, or radiotherapy within the last 4 weeks prior to entry in the study, or has not recovered from acute adverse events as a result of such therapy Has received prior hemibody external radiotherapy Has a need for immediate external radiotherapy Has received systemic radiotherapy with radium223, strontium89, samarium153, rhenium186 or rhenium188 for the treatment of bony metastases within the last 24 weeks prior to administration of study drug When receiving bisphosphonates, has changed the dose within 4 weeks before administration of study drug</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>BAY88-8223</keyword>
	<keyword>radium-223 dichloride</keyword>
	<keyword>prostate cancer</keyword>
</DOC>